Skip to content

The construction of an overall evaluation method for the clinical efficacy of TCM and western medicine in co-constructing parallel medical records

Clinical study to evaluate the real curative effect of Chinese and western medicine in the treatment of precancerous gastric cancer by doctor-patient parallel medical record

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022703
Enrollment
Unknown
Registered
2019-04-23
Start date
2019-05-01
Completion date
Unknown
Last updated
2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

precancerous gastric lesions

Interventions

Sponsors

Beijing Institute of Traditional Chinese Medicine Clinical Epidemiology and Evidence-Based Medicine Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients with precancerous lesions of the stomach that conform to the consensus opinion on chronic gastritis in China (2017, Shanghai) and the Kyoto global consensus opinion on helicobacter pylori gastritis; At the same time, the patient had the gastroscope and pathology of the first-grade hospital within three months, and the pathological report was clearly one of atrophy, intestinal metaplasia and epithelial neoplasia (dysplasia); (2) aged between 30 and 70 years; (3) The patient or family member knows the content of the study and voluntarily signs the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnancy or pregnancy preparation; 2. With acute cerebral vascular disease; 3. Surgery, major posttraumatic; 4. Patients with known malignant tumors, severe chronic heart, liver, renal insufficiency, and immune deficiencyhigh grade epithelial neoplasia and more severe cases; 5. The patient has a major mental illness or has difficulty controlling his behavior; 6. The patient can not read, can not understand the informed consent or can not sign the informed consent by themselves.

Design outcomes

Primary

MeasureTime frame
EBMRecord V1.0;OLGA gastric cancer risk staging rating;OLGIM gastric cancer risk staging rating;tissue grading of gastric mucosa;

Secondary

MeasureTime frame
economic indicators;

Countries

China

Contacts

Public ContactLi Bo

Beijing Institute of Traditional Chinese Medicine

dr.libo@vip.163.com+86 13811978473

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026